- BioMarin Pharmaceutical
BioMarin Pharmaceutical (NASDAQ|BMRN) is a biotechnology firm based in
Novato ,California . It has offices and facilities in the US, South America, and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin is the first company to provide therapeutics formucopolysaccharidosis type I (MPS I), by manufacturing Aldurazyme (commercialized byGenzyme Corporation). BioMarin is also the first company to provide therapeutics for Phenylketonuria(PKU) As of 2005, BioMarin commercialized
arylsulfatase B (Naglazyme) as an enzyme replacement therapy for the treatment ofmucopolysaccharidosis VI (MPS VI), and in 2007 a drug version oftetrahydrobiopterin (Kuvan), the first medication-based intervention to treatphenylketonuria . [cite news | url = http://www.nytimes.com/2007/12/14/health/14genetic.html?adxnnl=1&ref=us&adxnnlx=1207246157-x4BfrBsi1FBh9a8XYN40ig | title = Agency Approves Drug to Treat Genetic Disorder That Can Lead to Retardation | last = Pollack | first = A | date = 2007-12-14 | accessdate = 2008-04-03 | publisher =The New York Times ]References
External links
* [http://www.biomarinpharm.com/ Official site]
Wikimedia Foundation. 2010.